相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
Pasi A. Janne et al.
CANCER DISCOVERY (2022)
Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I
Archana Upadhya et al.
EXPERT OPINION ON DRUG DELIVERY (2021)
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
Xiuning Le et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma
Linghao Bu et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
Hao-Wen Sim et al.
NEURO-ONCOLOGY (2021)
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Martin van den Bent et al.
NEURO-ONCOLOGY (2020)
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
Antje Wick et al.
INVESTIGATIONAL NEW DRUGS (2020)
Management of glioblastoma: State of the art and future directions
Aaron C. Tan et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Targeting AKT for cancer therapy
Maryam Shariati et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Giuseppe Lombardi et al.
LANCET ONCOLOGY (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Sequencing the next generation of glioblastomas
Ivana Jovcevska
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2018)
Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma
Jacques Grill et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Temozolomide during radiotherapy of glioblastoma multiforme Daily administration improves survival
Silke Birgit Nachbichler et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2017)
Glioblastoma targeted therapy: updated approaches from recent biological insights
M. Touat et al.
ANNALS OF ONCOLOGY (2017)
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study
H. Ian Robins et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review
Kun Zou et al.
BMC CANCER (2016)
Survival in glioblastoma: a review on the impact of treatment modalities
P. D. Delgado-Lopez et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
Carmen Balana et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms
Stefan Klingler et al.
CANCER RESEARCH (2015)
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Edgar Perez-Herrero et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials
Julie A. Carlson et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEFaEuro
B. Chauffert et al.
ANNALS OF ONCOLOGY (2014)
Gain of Function of Mutant TP53 in Glioblastoma: Prognosis and Response to Temozolomide
Xiang Wang et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
The epidemiology of glioma in adults: a state of the science review
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
分享论文
